Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations

Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations

US Patent 9593333 · Granted Mar 14, 2017

Estimated economic value: $96,280,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Compositions and methods for diagnosis of cardiovascular disease2025
Modulating apolipoprotein (A) expression2025
Antibodies to oxidation-specific epitopes2025
Method of treating rheumatoid arthritis using antibodies to oxidized phospholipi2025
Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury2024
Antibodies to oxidized phospholipids2023
Therapies and methods to treat TLR2-mediated diseases and disorders2022
Modulating apolipoprotein (a) expression2022
Antibodies to oxidation-specific epitopes2021
Antibodies to oxidized phospholipids2021
Antibodies to oxidized phospholipids2021
Modulating apolipoprotein (a) expression2020